XML 45 R22.htm IDEA: XBRL DOCUMENT v3.19.3
SEGMENT REPORTING
9 Months Ended
Sep. 30, 2019
SEGMENT REPORTING  
SEGMENT REPORTING

16.  SEGMENT REPORTING

The Company reports in two reportable segments: Specialty and PBM. The Specialty segment offers a broad range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost specialty drugs and a wide range of applications and the PBM segment provides services designed to help the Company’s customers reduce the cost and manage the complexity of their prescription drug programs. The chief operating decision maker evaluates segment performance principally upon net sales and gross profit. Net sales, cost of sales and gross profit information by segment are as follows:

Three Months Ended September 30, 

Net Sales

Cost of Sales

Gross Profit

    

2019

    

2018

    

2019

    

2018

    

2019

    

2018

Specialty

$

1,243,448

$

1,212,298

$

(1,178,918)

$

(1,145,288)

$

64,530

$

67,010

PBM

 

82,500

 

169,933

 

(83,645)

 

(143,585)

 

(1,145)

 

26,348

Inter-segment eliminations

(24,751)

(8,897)

24,751

8,897

$

1,301,197

$

1,373,334

$

(1,237,812)

$

(1,279,976)

$

63,385

$

93,358

Nine Months Ended September 30, 

Net Sales

Cost of Sales

Gross Profit

    

2019

    

2018

    

2019

    

2018

    

2019

    

2018

Specialty

$

3,627,582

$

3,599,023

$

(3,432,506)

$

(3,386,653)

$

195,076

$

212,370

PBM

 

270,730

 

550,148

 

(250,474)

 

(480,365)

 

20,256

 

69,783

Inter-segment eliminations

(52,683)

(17,275)

52,683

17,275

$

3,845,629

$

4,131,896

$

(3,630,297)

$

(3,849,743)

$

215,332

$

282,153

Total assets by segment are as follows:

    

September 30, 

    

December 31, 

2019

2018

Specialty

$

968,956

$

1,045,174

PBM

 

193,647

 

431,185

$

1,162,603

$

1,476,359